Niraparib 200/300 MG

DRUG2 trials

Sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Pomeranian Medical University Szczecin

Conditions

Ovarian CancerRare Tumor

Phase 2

PLATFORM Study of Precision Medicine for Rare Tumors

RecruitingNCT04423185

Cancer Institute and Hospital, Chinese Academy of Medical SciencesRare Tumor

Start: 2020-08-15End: 2028-07-01Target: 770Updated: 2025-02-11

Unknown Phase

Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.

RecruitingNCT06614790

Pomeranian Medical University SzczecinOvarian Cancer

Start: 2024-09-02End: 2026-01-07Target: 300Updated: 2024-10-23

Related Papers

Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours

BMJ Open2021-06-019 citations